CatSci has opened an analytical science laboratory in Dagenham, UK with a focus on combining analytical and synthetic chemistry expertise with high-end equipment to solve industry problems.
The facility has been equipped analytical equipment through a collaboration with Shimadzu Corporation, providing analytical data and critical interpretation to customers and enabling them to reach the right decisions for their projects. A key early milestone in the company’s £3 m investment plan, the dedicated analytical resource is aimed to position CatSci as an innovation partner that can swiftly address evolving CMC challenges and pharmaceutical pipeline risks.
The demand for solving multi-disciplinary analytical problems is growing with the advent of modalities and asset classes like oligonucleotides and cannabinoids. At the same time, emerging or modified regulatory requirements such as nitrosamine determinations and trace impurity analysis require the development of specific and sensitive methods.
Dr Ross Burn, CEO, said: “The opening of our analytical laboratory at LondonEast in Dagenham, UK is an exciting step on our journey towards becoming a fully integrated CMC company that accelerates medicine development to deliver best-in-class therapeutics to those in need. Solving complex challenges that our customers face is at the core of what we do and this new facility, filled with Shimadzu’s cutting-edge equipment, sets a new exemplary standard for measurement science in the industry.”
Dr Nigel Richardson, Director of Analytical Technology & New Modalities, added: “We’re excited to leverage our large pharma heritage across the CMC landscape and excellence in analytical science to work seamlessly with our customers to solve their analytical chemistry challenges with speed and scientific integrity.
“The opening of this new facility deepens the level of support we can offer. We will also be upgrading the site with capacity for GMP analytical development and testing, which will further increase our ability to provide innovative, tailored solutions from early development pre-clinical data packages to late development Phase III impurity fate studies.”
